Device and surgical treatment of patients with heart failure based on the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

Authors

  • MOSCALU Vitalie Instituția medico-sanitară publică Institutul de Cardiologie
  • RACILA Valentin Instituția medico-sanitară publică Institutul de Cardiologie
  • RIZOV Mihail Instituția medico-sanitară publică Institutul de Cardiologie
  • GUȚAN Inesa Instituția medico-sanitară publică Institutul de Cardiologie

DOI:

https://doi.org/10.52692/1857-0011.2022.1-72.13

Keywords:

heart failure, implantable heart defibrillator, cardiac resynchronization therapy, electrical cardioversion, ablation, myocardial revascularization, mechanical circulatory support, heart transplant

Abstract

Management of all patients with heart failure and reduced left ventricular ejection fraction is based on optimal drug treatment - „the great four” that reduce mortality (1-angiotensin converting enzyme inhibitors or angiotensin receptor neprilyzine inhibitor; 2-beta-adrenoblockers; 3-mineralocorticoid receptor antagonists; 4-sodium-glucose cotransporter inhibitors-2). For certain categories of patients, treatments with implantable cardiac devices (CRT-P/D or ICD) and cardiac surgery (coronary artery bypass grafting, aortic or mitral valve repair operations) that improve the life prognosis are required, and for advanced heart failure may be considered methods of mechanical circulatory support and heart transplantation.

Author Biographies

MOSCALU Vitalie, Instituția medico-sanitară publică Institutul de Cardiologie

dr. șt. med., conf. cercetător

RACILA Valentin, Instituția medico-sanitară publică Institutul de Cardiologie

medic cardiolog

RIZOV Mihail, Instituția medico-sanitară publică Institutul de Cardiologie

medic cardiolog

GUȚAN Inesa, Instituția medico-sanitară publică Institutul de Cardiologie

medic cardiolog

References

Berliner D., Hänselmann A., Bauersachs J. The Treatment of Heart Failure with Reduced Ejection Fraction. Dtsch Arztebl Int., 2020 May 22; 117(21):376-386.

Cohn JN., Archibald DG., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med., 1986; 314:1547–1552.

Cunnington C., Kwok CS., et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. Heart., 2015; 101:1456–1462.

Ferrari R., Balla C., Fucili A. Heart failure: an historical perspective. Eur Heart J Suppl. 2016; 18(Suppl G):3–10.

Hai OY., Mentz RJ., Zannad F., Gasparini M., De Ferrari GM., et al. Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. Eur J Heart Fail., 2015; 17:135143.

Kirchof P,, Benussi S., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J., 2016.

Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, et al. ESC Scientific Document Group, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC., European Heart Journal., 2016; 37(27):2129-2200.

Podlesnikar, Tomaz et al. Imaging of Valvular Heart Disease in Heart Failure. Cardiac failure review. 2018; 4(2):78-86.

Shah SJ., Feldman T., Ricciardi MJ., et al. One year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAPHF I) Trial: a randomized clinical trial. JAMA Cardiol., 2018; 3:968-977.

Theresa A McDonagh, Marco Metra, Marianna Adamo et al. ESC Scientific Document Group, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal., 2021., 42(36):3599–3726.

Velazquez EJ., Lee KL., Deja MA., Jain A., Sopko G., Marchenko A., Ali IS., Pohost G., Gradinac S., Abraham WT., Yii M., Prabhakaran D., Szwed H., Ferrazzi P., Petrie MC., O’Connor CM., Panchavinnin P., She L., Bonow RO., Rankin GR., Jones RH., Rouleau JL., STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med., 2011; 364:1607-1616.

Velazquez EJ., Lee KL., Jones RH., Al-Khalidi HR., Hill JA., Panza JA., Michler RE., Bonow RO., Doenst T., Petrie MC., Oh JK., She L., Moore VL., DesvigneNickens P., Sopko G., Rouleau JL., STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med., 2016; 374:1511-1520.

Published

2022-04-08